Jean Jacques Bienaime has bought stock on 18 days since Apr 2017
Director at Ascendis Pharma A/S, and 4 other companies
SEC CIK 0001221590 · Filings on SEC.gov ↗
Jean Jacques Bienaime's record
3 months after each buy, from the first price a copier could get.
9 buys since 2017 with 3 months of prices.
Companies
Every filing
141 filings since Mar 2016, newest first
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Incyte Corp
Director
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Incyte Corp
Director
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
Biomarin Pharmaceutical Inc
CEO
About Jean Jacques Bienaime
Jean‑Jacques Bienaimé is an experienced biotechnology executive and individual corporate insider who serves as a non‑executive member of the Board of Directors of Ascendis Pharma A/S, where he was elected at the company’s Annual General Meeting in March 2026.( As a director, he has also reported open‑market purchases of Ascendis Pharma ordinary shares, including a buy of 400 shares on May 26, 2026, reflecting his role as an insider of the company.(
Bienaimé is best known for his long tenure at BioMarin Pharmaceutical Inc., where he served as Chief Executive Officer beginning in May 2005 and later as Chairman from June 2015 until his retirement in December 2023, leading the company through extensive growth in rare‑disease therapeutics.( Before BioMarin, he was Chairman, Chief Executive Officer, and President of Genencor Inc. from 2002 to 2005, and he has more than three decades of leadership experience in the biotechnology and pharmaceutical industries.( He currently serves on the boards of Incyte Corporation, Immunome, Inc., and Keros Therapeutics, Inc., among others, extending his influence across multiple innovative biopharmaceutical companies.( Bienaimé holds an M.B.A. from the Wharton School of the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris, providing a strong business and economic foundation for his executive and board responsibilities.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.